SCHEMBL29355604

SCHEMBL29355604

CC(=O)Oc1ccc2c(c1)Oc1cc(OC(C)=O)ccc1C21OC(=O)c2cc(CCl)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTP1 P09211 1/20 1.00
MAPT P10636 3/20 0.72
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
HTT P42858 2/20 0.72
ALDH1A1 P00352 2/20 0.72
USP2 O75604 2/20 0.72
LMNA P02545 1/20 0.72
CYP3A4 P08684 1/20 0.52
FTO Q9C0B1 9/20 0.47
RECQL P46063 2/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
BLM P54132 1/20 0.44
SMAD3 P84022 1/20 0.44
PRMT1 Q99873 1/20 0.44
ACE2 Q9BYF1 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KCNH2 Q12809 1/20 0.41
ITPR3 Q14573 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL329253 1.00 GSTP1 (1.00) GSTP1MAPTMEN1KMT2AHTT
SCHEMBL4204743 0.84 GSTP1 (0.73) GSTP1MAPTMEN1KMT2AHTT
SCHEMBL20353147 0.84 MAPT (0.78) GSTP1MAPTMEN1KMT2AHTT
Fluorescein Diacetate SCHEMBL29453229 0.84 MAPT (1.00) GSTP1MAPTMEN1KMT2AHTT
Fluorescein Diacetate SCHEMBL29353816 0.84 MAPT (1.00) GSTP1MAPTMEN1KMT2AHTT
Fluorescein Diacetate SCHEMBL1028369 0.84 MAPT (1.00) GSTP1MAPTMEN1KMT2AHTT
Fluorescein Diacetate SCHEMBL31658971 0.84 MAPT (1.00) GSTP1MAPTMEN1KMT2AHTT
SCHEMBL29403728 0.83 MEN1 (0.77) GSTP1MAPTMEN1KMT2AHTT
SCHEMBL18677730 0.83 MAPT (0.77) GSTP1MAPTMEN1KMT2AHTT
SCHEMBL12639984 0.83 MEN1 (0.77) GSTP1MAPTMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1674 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118995568-A Construction method and application of cholestasis organ model 北京清华长庚医院 2024-11-22 CN claimed
US-20240151731-A1 MEMBRANE PROTEIN INTERACTION SCREENING PLATFORM BASED ON CELL-CELL ADHESION EFFECTS SUZHOU INSTITUTE OF SYSTEMS MEDICINE (CN) 2024-05-09 US claimed
CN-117625727-A Evaluation method for in-vitro killing of tumor-infiltrating lymphocytes 北京臻知医学科技有限责任公司 2024-03-01 CN claimed
CN-114134198-B Reagent, device and method for rapid counting of eukaryotic microorganisms 国家粮食和物资储备局科学研究院 2024-01-26 CN claimed
US-20230341377-A1 DISCONNECTION AGENTS DC EUROPA LIMITED (GB) 2023-10-26 US claimed
WO-2023164252-A1 ISOTHERMAL NUCLEIC ACID DETECTION ASSAYS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2023-08-31 WO claimed
EP-4214505-A1 DISCONNECTION AGENTS DC Europa Limited (GB) 2023-07-26 EP claimed
CN-112782137-B Flow cytometer detection method for living plankton living cells with 10-50 mu m 自然资源部第一海洋研究所 2022-10-25 CN claimed
CN-115078231-A Ballast water microalgae microscopic imaging detection equipment and method 大连环信科技有限公司 2022-09-20 CN claimed
WO-2022058758-A1 DISCONNECTION AGENTS DC EUROPA LIMITED (GB) 2022-03-24 WO claimed
CN-114134198-A Reagent, device and method for rapidly counting eukaryotic microorganisms 国家粮食和物资储备局科学研究院 2022-03-04 CN claimed
US-20260144810-A1 mRNA COMPOSITION FOR TREATING CANCER, PREPARATION CONTAINING THE SAME AND USE THEREOF INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2026-05-28 US disclosed
CN-122094670-A Novel markers for tumor neoantigen vaccine 2026-05-26 CN disclosed
US-12637669-B2 Two-dimensional and three-dimensional microarray cell cultures using elastomeric assembly substrates NUTECH VENTURES (US) 2026-05-26 US disclosed
US-12637513-B2 Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein IMMUNEDGE, INC. (US) 2026-05-26 US disclosed
US-20220025053-A1 Methods of Inhibiting Metastasis in Cancer WISCONSIN ALUMNI RESEARCH FOUNDATION 2022-01-27 US disclosed
WO-2022016270-A1 FUSION PROTEINS COMPRISING A LIGAND-RECEPTOR PAIR AND A BIOLOGICALLY FUNCTIONAL PROTEIN ZYMEWORKS INC. (CA) 2022-01-27 WO disclosed
WO-2022020644-A2 THERAPEUTIC HYDROGEL FOR THE DELIVERY OF CAR-T CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-01-27 WO disclosed
EP-3672652-B1 ARTIFICIAL CARTILAGE AND METHOD FOR ITS PRODUCTION VETERINAERMEDIZINISCHE UNIV WIEN (AT) 2022-01-26 EP disclosed
EP-3942021-A1 METHOD OF IMPROVING THE IN VIVO SURVIVAL OF MESENCHYMAL STEM CELLS The Administrators of The Tulane Educational Fund (US) 2022-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637513-B2 Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein EPOR, MPL, CSF3R GSTP1 4066/4885MAPT 4634/4885MEN1 2590/4885
US-12637669-B2 Two-dimensional and three-dimensional microarray cell cultures using elastomeric assembly substrates EPCAM, STUB1, MEF2D GSTP1 4517/4885MAPT 141/4885MEN1 2304/4885
US-20260144810-A1 mRNA COMPOSITION FOR TREATING CANCER, PREPARATION CONTAINING THE SAME AND USE THEREOF CD47, IL2RA, IL2 GSTP1 4568/4885MAPT 2047/4885MEN1 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.